Subscribe to Press Releases


Immunotherapies for Life

YmAbs to Present Company Overview at the 35th Annual J.P. Morgan Healthcare Conference 2017


Y-mAbs Therapeutics, Inc. invited to present at leading healthcare conference

NEW YORK, January 4, 2017 – Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that it is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 10, 2017 at 1:30 p.m. PST (4:30 p.m. EST). Dr. Claus Møller, YmAbs’ Chief Executive Officer, will be the presenter.


About YmAbs

YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7H3. To further improve our bispecific antibodies, we are collaborating on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

To learn more, visit



Y-mAbs Therapeutics, Inc.


 Y-mabs Therapeutics, Inc.

 750 Third Avenue, 9th Floor

 New York, NY 10017


 +1 212 847 9841


     Y-mAbs Therapeutics A/S

     Rungsted Strandvej 113

     2960 Rungsted Kyst


     +45 70 26 14 14